Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway - Wikidata - awgldk - TriplyDB

Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway

Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway

http://www.wikidata.org/entity/Q35545549

about

NOX2-Induced Activation of Arginase and Diabetes-Induced Retinal Endothelial Cell Senescence.Tissue-specific up-regulation of arginase I and II induced by p38 MAPK mediates endothelial dysfunction in type 1 diabetes mellitus.Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications.Vascular surgical stretch injury leads to activation of P2X7 receptors and impaired endothelial function.EPA:DHA 6:1 prevents angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase- and COX-derived oxidative stress.Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.Mechanisms of Diabetes-Induced Endothelial Cell Senescence: Role of Arginase 1.

P2860

Q33845094-8B14B8EE-139D-4AF4-B694-0359CD912B18 Q36124220-281FDFE3-0581-461F-B9B0-36C5F9DDED65 Q37728038-DD72EF88-0CC4-4D4A-941E-00C12973DECC Q46856693-20722949-C6C3-46D6-9834-4BE82C8BA2F7 Q47845782-709D0F90-5E81-410D-9F07-82950869A37F Q52716813-013A7A03-301C-4E28-BF95-256DFE99A6B5 Q55153776-3B599CD2-B269-48E3-AF86-834703051093

P2860

Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway

http://www.wikidata.org/entity/Q35545549

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Angiotensin II limits NO produ ...... rough a p38 MAPK-ATF-2 pathway

@ast

Angiotensin II limits NO produ ...... rough a p38 MAPK-ATF-2 pathway

@en

type

label

Angiotensin II limits NO produ ...... rough a p38 MAPK-ATF-2 pathway

@ast

Angiotensin II limits NO produ ...... rough a p38 MAPK-ATF-2 pathway

@en

prefLabel

Angiotensin II limits NO produ ...... rough a p38 MAPK-ATF-2 pathway

@ast

Angiotensin II limits NO produ ...... rough a p38 MAPK-ATF-2 pathway

@en

P1433

Q35545549-F1A3FDE9-2F90-4DCB-9B05-D3BDF375D1C0

P1476

Q35545549-040E429C-8C96-4BF5-A5C2-E8E39FFFACE1

P2093

Q35545549-9C765739-821A-425E-9DF9-4478D674ECC3

Q35545549-9D953676-C865-4977-9F8B-3E3FE25CA34B

Q35545549-A70A387C-B684-4B29-BA6F-FB8C11D0F27E

Q35545549-B2871BC5-6FC1-4436-BB68-0AD2150AC96C

Q35545549-DF0D5D87-DFB2-40E0-B0CB-7FCE6FF73614

P2860

Q35545549-078D46D5-741F-49C0-9875-F30368F7131D

Q35545549-0FF6BA1A-2211-4568-9D01-5CB420DF4CAA

Q35545549-10205873-357C-4A0A-8E14-920539B9D0CB

Q35545549-1BC32E1F-F81F-4417-8F33-9436A5B3B9C8

Q35545549-1C2EB1D4-F5B8-4B49-A9D9-4C3B591E567A

Q35545549-244A85B4-072D-4A0A-85FA-49D9BE9F7FF4

Q35545549-2BB66964-1FC3-4D52-BD87-8C2924BFE458

Q35545549-2CA17875-7761-4865-85B7-CC19CE9C46B7

Q35545549-36EF676A-B331-4644-85E9-6B40D38DDCCA

Q35545549-49693872-5E46-4791-88D3-845A64951828

P304

Q35545549-459F1250-DFF3-4E8D-A703-C452583DD484

P31

Q35545549-B92F584C-6BD3-4B9A-AA14-3D422DEF3C5A

P356

Q35545549-ECA38F8E-7BF5-4B0B-BB4D-8911279B1DE4

P407

Q35545549-4F0AB1F3-F352-42AE-88D6-C857D54BEB84

P478

Q35545549-92A43B44-2A75-4618-B01D-5BEB857E4CF8

P50

Q35545549-782CBC2F-9CDD-41EA-B9AF-423E31F529F3

P577

Q35545549-725ED254-0D2D-4EBA-A8E9-03584BCCB117

P5875

Q35545549-CD4B1B23-586C-401D-B32A-127A5D31D927

P698

Q35545549-C90EBDAA-5042-4E43-A083-D55BDB92D82F

P932

Q35545549-23D794B1-B0E0-4AB3-B699-ABE4D5DAEBF7

P356

J.EJPHAR.2014.10.042

P1433

European Journal of Pharmacology

P1476

Angiotensin II limits NO produ ...... rough a p38 MAPK-ATF-2 pathway

@en

P2093

Chintan Patel

http://www.w3.org/2001/XMLSchema#string

Lin Yao

http://www.w3.org/2001/XMLSchema#string

R William Caldwell

http://www.w3.org/2001/XMLSchema#string

Ruth B Caldwell

http://www.w3.org/2001/XMLSchema#string

Tahira Lemtalsi

http://www.w3.org/2001/XMLSchema#string

P2860

IRF2-binding protein-1 is a JDP2 ubiquitin ligase and an inhibitor of ATF2-dependent transcription

Mouse model for human arginase deficiency

ATF-2 contains a phosphorylation-dependent transcriptional activation domain

Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine

AT(1) receptor activation regulates the mRNA expression of CAT1, CAT2, arginase-1, and DDAH2 in preglomerular vessels from angiotensin II hypertensive rats

Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress

Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy.

Thrombin induces endothelial arginase through AP-1 activation.

Emerging roles of ATF2 and the dynamic AP1 network in cancer.

p38 Mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II-treated mice

P304

106-114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJPHAR.2014.10.042

http://www.w3.org/2001/XMLSchema#string

P407

P478

746

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269176821

http://www.w3.org/2001/XMLSchema#string

P698

25446432

http://www.w3.org/2001/XMLSchema#string

P932

4412038

http://www.w3.org/2001/XMLSchema#string